The Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA) are officially introducing a new medical trial authorization system. The reform aims to eliminate unnecessary bureaucracy and accelerate patient access to innovative therapies while maintaining the highest safety standards.
The new system facilitates support for the early stages of research and embraces modern technologies. The regulations allow for the broader use of early safety data from foreign centers (provided they meet UK standards) and the use of computer simulations to predict the behavior of new drugs before administering them to patients. Crucially for transparency, the registration of clinical trials and the publication of their summaries become a legal requirement under the new rules.
One of the cornerstones of the reform is the permanent introduction of “Route B” – a mechanism facilitating substantial modifications to ongoing trials that do not introduce new risks. The pilot program for this solution, conducted at the turn of 2025 and 2026, was a massive success: over half of the applications came from commercial sponsors, and the average processing time was just 7 days. As of April 28, Route B becomes law: qualifying modifications are now approved automatically unless the regulatory body raises objections within 14 calendar days.
Dr. Zubir Ahmed, UK Minister for Innovation and Health Security, emphasized the importance of these changes in his statement:
“This is a landmark moment for patients, researchers, and our thriving life sciences sector that will make a real, tangible difference for thousands of people waiting for new treatments. By introducing faster routes for lower-risk trials, embracing modern technology, and making the system simpler to navigate, we are reinforcing the UK’s position as one of the most attractive places in the world to invest in cutting-edge research.”
The government has managed to significantly exceed its own 10-year plans for the NHS, which aimed to cut clinical trial setup times to 150 days. As Dr. Ahmed added:
“The government set itself an ambitious target to cut clinical trial set-up times to 150 days — and I’m proud to say we’ve gone further and faster than that. We have driven those times down to just 122 days from 169 this time last year for commercial trials, meaning patients across the UK are getting the latest, most innovative treatments sooner than ever before.”
This time reduction was made possible, in part, by an integrated safety and ethics review process. The average time for this combined verification conducted by the MHRA and HRA is now 41 days – more than twice as fast as just a few years ago.
Representatives of regulatory bodies also weighed in on the matter. Lawrence Tallon, Chief Executive of the MHRA, highlighted the market and health benefits:
“These reforms to clinical trial regulations are a boost both for patients and industry investment in R&D in this country. They will help to make the UK a more attractive, internationally competitive destination for both commercial and non-commercial clinical research. Most importantly, patients will benefit from earlier access to the latest, innovative medicines.”
Meanwhile, Matt Westmore, Chief Executive of the HRA, pointed out that the biggest winner of the new law will be public trust in medicine:
“The updated regulations will bring greater transparency, faster approvals for clinical trials and simpler approaches for low-risk trials – making it quicker and easier to set up and run trials while placing patients at the centre of medical research. Not only will the new framework speed up vital research that could lead to innovative and improved treatments for patients, but it will support a streamlined, joined up and proportionate clinical research system.”